Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retifanlimab + Chemotherapy in First-Line Metastatic NSCLC
NCT04205812Phase 3Completed
- Sponsor
- Incyte
- Start
- Sep 2020
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial of retifanlimab in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Incyte. Primary endpoint: Overall Survival up to 39.1 months. Started Sep 2020; status: completed.
02
Drugs
retifanlimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04205812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04205812.